O slideshow foi denunciado.
Utilizamos seu perfil e dados de atividades no LinkedIn para personalizar e exibir anúncios mais relevantes. Altere suas preferências de anúncios quando desejar.

Pharma Marketing News 2016 Year in Review: Charts & Graphs

4.954 visualizações

Publicada em

Charts, graphs, and data published in 2016 by Pharma Marketing News and Pharma Industry Update.

Publicada em: Saúde e medicina

Pharma Marketing News 2016 Year in Review: Charts & Graphs

  1. 1. 2016. Pharma Marketing Network. All rights reserved. The Year 2016 in Charts & Graphs TM
  2. 2. 2016. Pharma Marketing Network. All rights reserved. FDA Drug Approvals Up, Up, & Away! NME = New Molecular Entity BLA = Biologicals http://sco.lt/8qWLxJ
  3. 3. 2016. Pharma Marketing Network. All rights reserved. But Drug Approvals & R&D ROI Drop in 2016! http://sco.lt/6QmBhR
  4. 4. 2016. Pharma Marketing Network. All rights reserved. Path Taken by Sarepta NOT a Good Model for Other Rare Drug Approvals In a presentation at a summit meeting of the National Organization of Rare Diseases on Tuesday, October 16, 2016, John Jenkins, director of the office of new drugs at the Center for Drug Evaluation and Research, singled out the eteplirsen case as a new textbook example of what other companies should avoid. http://sco.lt/7stCs5 A few weeks later, CDER director and Sarepta champion Janet Woodcock spread the word that Jenkins is retiring from the FDA in early January — and she’s temporarily assuming his position. http://sco.lt/8CkEpl
  5. 5. 2016. Pharma Marketing Network. All rights reserved. FDA to Device Makers: Want Faster Approval? Then Pay Up! Former FDA Commissioner Dr. Hamburg admitted that FDA has essentially "lowered some [drug] approval standards" but when asked why medical devices were not being given the same rapid approval treatment, Dr. Hamburg stated that "[a] higher percentage of our overall drug program (is supported by fees from drug makers).” http://sco.lt/7bzCbp
  6. 6. 2016. Pharma Marketing Network. All rights reserved. Cost to Bring a New Drug to Market is Increasing – Or Is It? Tufts revised its estimate of the cost to bring a new drug to market to be $2.6 billion, which is 3.25 times its widely quoted 2003 estimate of $800 million. Meanwhile, the London School of Economics and political Sciences (LSEPS) suggests this number is highly inflated, even if you take out the “cost of capital,” which is not real money spent by pharma. http://bit.ly/newtufts
  7. 7. 2016. Pharma Marketing Network. All rights reserved. Wide Range of R&D Cost Estimates In September, 2016, the United Nations released a report urging governments to take various steps to ensure greater access to needed medicines. The report claims that not enough is being done to develop drugs to treat diseases that pre- dominantly afflict poor populations. The Pharmaceutical Research & Manufacturers of America was not pleased, though. The industry trade group called the report a “a missed opportunity to address the wide array of barriers to access that far too many people face every day.” http://sco.lt/6znt6v
  8. 8. 2016. Pharma Marketing Network. All rights reserved. Vaccines Are Path to Revenue Growth The revenue growth opportunity in vaccines looks far more promising when compared to the overall market for pharmaceuticals. Revenues earned by vaccines manufacturers worldwide reached $27.6 billion in 2015 according to Kalorama Information, up 11% from $24.7 billion in 2014, as sales in all segments expanded. http://sco.lt/582wTZ
  9. 9. 2016. Pharma Marketing Network. All rights reserved. Facts About Prescription Drug Spending http://sco.lt/8vUQ7d
  10. 10. 2016. Pharma Marketing Network. All rights reserved. The Awful State of U.S. Life Expectancy Despite Awesome Dollars Spent on Healthcare! http://sco.lt/4ut8JF
  11. 11. 2016. Pharma Marketing Network. All rights reserved. How Much Does Pharma Lose Each Year Due to Medication Nonadherence? http://sco.lt/8HUJVZ
  12. 12. 2016. Pharma Marketing Network. All rights reserved. Branded DTC Ad Spend Ties Record High! It’s a tie. Pharma advertisers spent $5.4 billion in 2015, tying the previous industry record set in 2006, according to new data from Kantar Media. That's an increase of 19% over the category's $4.53 billion tally for 2014. http://sco.lt/7EvRPl
  13. 13. 2016. Pharma Marketing Network. All rights reserved. Overall DTC Ad Spend Set New Record! Consumer ad spending by drug makers in 2015 reached $6.09 billion ... after $5.12 billion was spent in 2014 and $4.29 billion was spent in 2013. These totals include spending on branded prescription drug ads plus unbranded ads by drug companies promoting disease awareness. http://sco.lt/5LXd2X
  14. 14. 2016. Pharma Marketing Network. All rights reserved. The Boom in DTC TV Advertising! The portion of DTC spending on TV has increased from 55% in 2011 to 69% in 2015. Will this boom continue? Most likely, yes! Read: “Big Pharma Spending on TV Ads Like a Drunken Sailor.” http://sco.lt/8epI6z
  15. 15. 2016. Pharma Marketing Network. All rights reserved. Top 10 Rx TV Ad Spends Pfizer owned TV ad spending for 2015 among pharma brands. It took 5 spots on the top 10 list for the year, including Nos. 1 and 2, according to iSpot.tv. http://sco.lt/8KZEAb
  16. 16. 2016. Pharma Marketing Network. All rights reserved. Fair Balance & Adequate Provision in Drug Banner Ads http://sco.lt/94ChAP
  17. 17. 2016. Pharma Marketing Network. All rights reserved. Only 1 Top 10 Pharma Spends a Bit More on R&D Than Marketing http://sco.lt/6EZCzJ
  18. 18. 2016. Pharma Marketing Network. All rights reserved. Drugs for Older Americans Rose 15.5% in 2015 http://sco.lt/4pzEKv
  19. 19. 2016. Pharma Marketing Network. All rights reserved. The Pain in Spain: Naked Celebrities Promote Oxycontin Prescriptions for OxyContin have fallen nearly 40% since 2010. So the company’s owners, the Sackler family, are pursuing a new strategy: Put the painkiller that set off the U.S. opioid crisis into medicine cabinets around the world. In this global drive, the companies, known as Mundipharma, are using some of the same controversial marketing practices that made OxyContin a pharmaceutical blockbuster in the U.S. Seeking new patients in Spain, for example, Mundipharma chose ambassadors guaranteed to attract attention: Naked celebrities. http://sco.lt/8LFSuv
  20. 20. 2016. Pharma Marketing Network. All rights reserved. Questions About FDA Regulation of EpiPen Competition Five US senators wrote the FDA to express concerns the agency may have helped stifle EpiPen competition. And in their letter to FDA Commissioner Dr. Robert Califf, the lawmakers worry the FDA is not doing enough to ensure that competitive versions are available, especially given that epinephrine - the main ingredient in EpiPen - has been on a drug shortage list since 2012. Find the list of questions here: http://sco.lt/6RgsUb
  21. 21. 2016. Pharma Marketing Network. All rights reserved. Tracking Who Makes Money On A Brand-Name Drug Kaiser Health News joined forces with USA Today to create this chart, which details the various industry players and how they contribute to a prescription drug’ s cost. See the entire chart here... http://sco.lt/7h31Ht No matter what the "middlemen" make, drug price INCREASES start at the top; i.e., the drug company.
  22. 22. 2016. Pharma Marketing Network. All rights reserved. Content Channel Value as Seen by Docs vs. Pharma A study by EPG Health Media, publisher of epgonline.org (a website for healthcare professionals) found some "significant gaps and imbalances" between how healthcare professionals (HCPs) and pharma industry professionals (Pharma) view the value of medical content delivery channels. For example, pharma professionals think rep visits are much more valuable sources of medical information than do HCPs and HCPs believe medical apps may be important content sources, but not as valuable as pharma professionals think they are. But there are some devils in the details. http://sco.lt/6c7IcD
  23. 23. 2016. Pharma Marketing Network. All rights reserved. Only 10% of Docs Prefer Info Direct from Pharma to Make Treatment Decisions http://sco.lt/8JgzoX
  24. 24. 2016. Pharma Marketing Network. All rights reserved. Physicians Prefer Pharma Info Via Email http://sco.lt/64fpab
  25. 25. 2016. Pharma Marketing Network. All rights reserved. Pharma Sales Reps: Declined & Denied! http://sco.lt/6TCKNl
  26. 26. 2016. Pharma Marketing Network. All rights reserved. Growth/Decline in Pharma Support of CME The total commercial (i.e., pharma) support of accredited continuing medical education was $1.08 billion in 2015 – a 5.2% increase over 2015. Perhaps the pharma industry was anticipating that the 21st Cures Act would exclude CME payments from the reporting requirements of the Sunshine Law. Alas, that provision did not make in the final version that the Senate sent to the present in December 2016. Or perhaps the industry has just learned to live with the sunshine and really, really needs to educate physicians about all the new and complex drugs being approved by the FDA these days. http://sco.lt/7yzXl3
  27. 27. 2016. Pharma Marketing Network. All rights reserved. Last Minute Uptick in FDA Letters for 2016 FDA’s Office of Prescription Drug Promotion is dredging the bottom of the barrel and issued 6 enforcement letters in the last weeks of December, 2016 to bring the total to 11 for the year. All this smacks of getting some last licks in before a new FDA commissioner takes over. http://sco.lt/6HUSgL
  28. 28. 2016. Pharma Marketing Network. All rights reserved. FDA Enforcement vs. PDUFA Fees Research suggests that drugs released after the 1992 enactment of the Prescription Drug User Fee Act (PDUFA), which allowed the FDA to collect fees to expedite drug approvals, were more likely to be withdrawn or have a black box warning. As this chart shows, as FDA collects more fees, it issues fewer enforce- ment letters. Coincidence? http://sco.lt/8CCwW9
  29. 29. 2016. Pharma Marketing Network. All rights reserved. Dramatic Increase in Drug Adverse Events In 2014 more AERs were submitted by consumers than by Health Care Professionals (HCPs) of all types. Not only is the FDA receiving more AERs every year, the number of serious AEs and AEs involving death are also increasing dramatically. http://sco.lt/8pXZD7
  30. 30. 2016. Pharma Marketing Network. All rights reserved. FDA User Fees & the Increase in Serious AERs I decided to plot the number of AERs involving serious side effects along with the rise in user fees collected by the FDA from pharma companies and came up with this chart. Of course, this does not prove a correlation between PDUFA fees and serious AERs, but… http://sco.lt/8pXZD 7
  31. 31. 2016. Pharma Marketing Network. All rights reserved. 25 Years of Pharma Criminal & Civil Penalties http://sco.lt/8iZzd3
  32. 32. 2016. Pharma Marketing Network. All rights reserved. Pharma's Rep Among Patient Groups at 4-Year High http://sco.lt/6eoNgf
  33. 33. 2016. Pharma Marketing Network. All rights reserved. Pharma Criminal & Civil Penalty Challenge In a March, 2016, report, Public Citizen tallied all drug industry settlements with both federal and state governments from 1991 through 2015. When readers of Pharma Marketing Blog were challenged to rank the Top 10 of those companies in terms of the amount paid over those 10 years, only one person was able to do so. The correct rank of each company is circled in this chart of response results. Some surprises: Only 5% of respondents correctly ranked AZ last whereas 31% thought it ranked in the top 3. 21% of respondents correctly ranked J&J as #3, but that may because I gave hints along the way via Twitter. 70% of respondents ranked Teva as #9 or #10 and only 9% correctly ranked it as #7 on the list. http://sco.lt/6z3eAD
  34. 34. 2016. Pharma Marketing Network. All rights reserved. Social Media & the Written Word Here is a breakdown of the current stats relating to my Internet publishing activities over the years: Pharma Marketing News (started January 2002) • 639 articles • Over 1.2 million words (1800 words per article) Pharma Marketing Blog (started January 2005) 2393 posts • Over 2.3 million words (554 words per post) Pharmaguy on Twitter (started March 2008) • Over 26,000 tweets • Over 0.5 million words (21 words per tweet) Do you see the trend? http://sco.lt/6kdu1B
  35. 35. 2016. Pharma Marketing Network. All rights reserved. Wishing You a Happy New Year!

×